Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets slip
Wed, 30 Apr 01:30 pm

Indian share markets pared early gains and drifted in the negative territory in the post-noon trading session. Majority of the sectoral indices are trading in the red with realty and metal stocks being the biggest losers. Oil & gas and auto are among the few indices trading positive.

BSE-Sensex is down 7 points and NSE-Nifty is trading 9 points down. BSE Mid Cap is trading 0.7% down and BSE Small Cap index is trading down by 0.8%. The rupee is trading at 60.3 to the US dollar.

Majority of the FMCG stocks are trading in the green with P&G Hygiene and Lakshmi Energy being the major gainers whereas Hindustan Unilever and Kokyo Camlin are a few stocks trading in the red. Bajaj Corp (BCL) has announced results for the quarter ended March 2014. The company clocked flat topline in 4QFY14 on a 6.4% YoY decline in offtake. However, the company has managed to improve operating margin by 0.4% YoY backed by lower ad-spends and reduced raw material costs and wages. Excluding the impact of brand amortization of Rs 117.5 m, the net profits have grown by 1.8% in 4QFY14 aided by lower tax outgo. For FY14, revenues grew by 11% YoY led by a volume growth of 6%. The operating margin contracted by 0.7% YoY for the year due to steep rise in other expenses. The net profits without brand amortization have grown by a relatively slower 7% YoY due to high interest outgo during the year. Bajaj Corp stock is presently trading down 2.4%.

Indian pharma stocks are trading mixed today. While JB Chemicals and Natco Pharma are trading weak, Glenmark Pharma and IPCA Labs are trading higher. As per a leading business daily, Aurobindo Pharma is facing patent infringement and violation cases against its three generic drug applications in the US. Three companies in the US have filed the cases against Aurobindo for violation of patent against their drugs. These include the company's ANDA (abbreviated new drug application) for generic version of dexmedetomidine hydrochloride injection which is used as sedative and is facing patent allegation by Hospira for the drug Precedex. Two other companies have filed for violation of patents against Aurobindo for their drugs Angiomax (bivalirudin) and Livalo (Pitavastatin). While the company believes such cases are quite common in the industry, any adverse ruling can affect the company's revenues during the exclusivity period. The stock of Aurobindo Pharma is trading higher by 0.4% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets slip". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.